First Mid Bancshares, Inc. (NASDAQ: FMBH) (the "Company") today announced its financial results for the quarter ended March 31, 2025. Highlights Record ...

Revenue, Adjusted EBITDA1 and Adjusted Free Cash Flow1 all ahead of expectations Net Leverage1 of 3.1x, lowest in Company's history Revenue of $1,560.1 million ...

Net sales in the first quarter of 2025, which had two fewer selling days compared to the first quarter of 2024, decreased 1%(a). Gross profit in the first quarter of 2025 was $627 million, a decrease ...

The fund has adopted a managed distribution plan. Under a managed distribution plan, to the extent that sufficient investment income is not available on a monthly basis, the fund will distribute ...

Net leverage was calculated by dividing net debt as of March 31, 2025 and December 31, 2024 by adjusted EBITDA for the last twelve months ended March 31, 2025 and year ended December 31, 2024, ...

Lavina Talukdar; Senior Vice President & Head of Investor Relations; Moderna Inc. Stephane Bancel; Chief Executive Officer, Director; Moderna Inc. James Mock; Chief ...

Jonathan Olsen; Chief Financial Officer, Executive Vice President, Treasurer; Invitation Homes Inc Scott Eisen; Executive Vice President, Chief Investment Officer; Invitation Homes Inc Michael ...

Good morning ladies and gentlemen, and welcome to Patrick Industries first quarter of 2025 earnings conference call. My name is Shamali, and I'll be your operator for today's call. (Operator ...

Peoples Financial Services Corp. ("Peoples" or the "Company") (NASDAQ: PFIS), the bank holding company for Peoples Security ...

Envista Holdings Corporation (NYSE: NVST) today announced results for the quarter ended March 28, 2025. "In the first ...

Financial Highlights Revenue of $157 million increased 17% sequentially Net income before taxes and discontinued operations of $5.1 million decreased ...

Topline histology data from ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials are expected in 1H 2027 and in 2028, respectively; each trial is designed to support accelerated approval to treat ...